Reimbursement Review Reports

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Sort ascending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Xtandi Enzalutamide First Line Metastatic Castration-Resistant Prostate Cancer Reimburse with clinical criteria and/or conditions Complete
Xtandi Enzalutamide Metastatic Castration Resistant Prostate Cancer Reimburse with clinical criteria and/or conditions Complete
Xpovio selinexor Multiple myeloma Reimburse with clinical criteria and/or conditions Complete
Xospata Gilteritinib Reimburse with clinical criteria and/or conditions Complete
Xolair Omalizumab (Drug Plan Submission) Asthma, severe persistent Reimburse with clinical criteria and/or conditions Complete
Xolair omalizumab Chronic rhinosinusitis with nasal polyps CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer Not filed
Xolair Omalizumab Asthma, severe persistent Cancelled
Xolair Omalizumab Asthma, severe persistent Do not list Complete
Xolair Omalizumab Chronic idiopathic urticaria List with clinical criteria and/or conditions Complete
Xofluza baloxavir marboxil Influenza CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer